title: Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
abstract: The etonogestrel (ENG) contraceptive implant is the most effective reversible contraceptive method. Uptake remains limited in adolescents, a population at high risk for unintended pregnancy. The objectives of this study were to determine the 12-month discontinuation rate of the ENG implant among adolescents in an outpatient setting and to characterize risk factors for discontinuation.
  
  
  
  A retrospective chart review identified adolescent females aged 12 to 22years who received the ENG implant in one pediatric institution between January 1, 2011, and April 15, 2014. Patients were categorized into ENG discontinuers (removed prior to 12months) and ENG continuers (continued for ≥12months). Associations between demographic, clinical and postplacement characteristics with ENG discontinuation category were assessed with t tests, χ(2)/Fisher's Exact Tests and backwards stepwise logistic regression.
  
  
  
  Of the 750 patients who had an ENG implant inserted, 77 (10.3%) had the device removed prior to 12months of use. The mean length of implant use for those who discontinued was 7.5months. Problematic bleeding was the most commonly cited reason for discontinuation. Older age at time of insertion, history of pregnancy and ≥1 medical visit for implant concerns (not including removal) were independently predictive (p<.01) of method discontinuation.
  
  
  
  The vast majority of adolescents continued the ENG implant at 12months, making it an excellent contraceptive choice for adolescents within the outpatient pediatric setting. Greater efforts should be made to increase its use by pediatric providers.
  
  
  
  The ENG implant is an excellent contraceptive option for adolescents in the outpatient pediatric setting.
authors.affiliation: Section of Adolescent Medicine, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH. Electronic address: elise.berlan@nationwidechildrens.org.
authors.forename: Elise
authors.initials: E
authors.lastname: Berlan
authors.affiliation: The Ohio State University College of Medicine, Columbus, OH.
authors.forename: Kelly
authors.initials: K
authors.lastname: Mizraji
authors.affiliation: Section of Adolescent Medicine, Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH.
authors.forename: Andrea E
authors.initials: AE
authors.lastname: Bonny
mesh_terms: D000293:Adolescent; D002648:Child; D003267:Contraception / Q000706:statistics & numerical data; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000627:therapeutic use*; D017135:Desogestrel / Q000008:administration & dosage / Q000627:therapeutic use*; D020878:Device Removal / Q000706:statistics & numerical data*; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D016015:Logistic Models; D015999:Multivariate Analysis; D010045:Outpatients; D011247:Pregnancy; D011253:Pregnancy in Adolescence / Q000517:prevention & control*; D012189:Retrospective Studies; D013997:Time Factors; D014481:United States; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; C044815:etonogestrel; D017135:Desogestrel
keywords: Adolescents; Contraception; Etonogestrel; Implant; Pediatric; Pediatrician